Form 13-F position report

VIRACTA THERAPEUTICS INC (CAN)

Reported by RP Management LLC

VIRX CUSIP 92765F108 Manager CIK 0001507673

Reported 3,700 shares, unchanged from the prior quarter.

Reported value 0.0%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 3,700 Quarter-end amount reported
Reported value $18,000 Fair value at quarter end
Consecutive quarters held 6 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 34000
2021-06-30 42000
2021-09-30 30000
2021-12-31 13505000
2022-03-31 18000
2022-06-30 18000
2022-09-30 16000
2022-12-31 5402
2023-03-31 5883
2023-06-30 5217
2023-09-30 3848
2023-12-31 2109
2024-03-31 3774
2024-06-30 1998
2024-09-30 851
2024-12-31 851
2025-03-31 74

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for VIRACTA THERAPEUTICS INC (CAN) held by RP Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2025 Unchanged 3,700 0 (0.0%) < 0.01% $74 2025-05-02
Q4 2024 Unchanged 3,700 0 (0.0%) < 0.01% $851 2025-02-03
Q3 2024 Unchanged 3,700 0 (0.0%) < 0.01% $851 2024-11-13
Q2 2024 Unchanged 3,700 0 (0.0%) < 0.01% $1,998 2024-08-13
Q1 2024 Unchanged 3,700 0 (0.0%) < 0.01% $3,774 2024-05-08
Q4 2023 Unchanged 3,700 0 (0.0%) < 0.01% $2,109 2024-02-13
Q3 2023 Unchanged 3,700 0 (0.0%) < 0.01% $3,848 2023-11-13
Q2 2023 Unchanged 3,700 0 (0.0%) < 0.01% $5,217 2023-08-11
Q1 2023 Unchanged 3,700 0 (0.0%) < 0.01% $5,883 2023-05-15
Q4 2022 Unchanged 3,700 0 (0.0%) < 0.01% $5,402 2023-02-14
Q3 2022 Unchanged 3,700 0 (0.0%) < 0.01% $16,000 2022-11-14
Q2 2022 Unchanged 3,700 0 (0.0%) < 0.01% $18,000 2022-08-10
Q1 2022 Unchanged 3,700 0 (0.0%) < 0.01% $18,000 2022-05-11
Q4 2021 Unchanged 3,700 0 (0.0%) 5.65% $13,505,000 2022-02-14
Q3 2021 Unchanged 3,700 0 (0.0%) 0.01% $30,000 2021-11-15
Q2 2021 Unchanged 3,700 0 (0.0%) 0.02% $42,000 2021-08-12
Q1 2021 New 3,700 +3,700 (0.0%) 0.01% $34,000 2021-05-17

Who else reported the position

78 managers reported VIRACTA THERAPEUTICS INC (CAN) for Q2 2022.

Managers reporting VIRACTA THERAPEUTICS INC (CAN) in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BVF INC IL Unchanged 3,614,662 0 0.68% $14,025,000 6 qtrs
CITADEL ADVISORS LLC Reduced 1,556,222 -8,792 < 0.01% $6,038,000 6 qtrs
VANGUARD GROUP INC Added 907,260 +78,383 < 0.01% $3,520,000 6 qtrs
Laurion Capital Management LP New 698,000 +698,000 0.04% $2,708,000 1 qtr
Samsara BioCapital LLC Reduced 689,709 -21,330 0.71% $2,676,000 6 qtrs
MAI Capital Management Added 647,950 +267,162 0.05% $2,514,000 2 qtrs
BlackRock Inc Reduced 542,431 -1,770,477 < 0.01% $2,104,000 6 qtrs
ADAGE CAPITAL PARTNERS GP L L C Added 470,000 +216,309 < 0.01% $1,824,000 2 qtrs
MILLENNIUM MANAGEMENT LLC New 316,309 +316,309 < 0.01% $1,227,000 1 qtr
Aisling Capital Management LP Unchanged 288,571 0 0.8% $1,120,000 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 10, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
3,700
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.